ライフサイエンスコーパス: in the treatment of

1 s the regenerative effects observed with PRF in the treatment of 3-wall IBDs.

2 ation and suggest their possible application in the treatment of a range of inflammatory conditions.

3 cycline chemotherapeutic agent commonly used in the treatment of a wide range of cancers.

4 uate the durability of response to rituximab in the treatment of acetylcholine receptor autoantibody-

5 In the treatment of acute bacterial skin and skin struct

6 ileukemic drug asparaginase, a key component in the treatment of acute lymphoblastic leukemia, acts b

7 (Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction [PRAGUE-

8 For >4 decades, the holy grail in the treatment of acute myocardial infarction has been

9 E-18 (Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction) study d

10 um toxin is at least as effective as surgery in the treatment of acute-onset comitant esotropia at 6

11 toxin is as effective as strabismus surgery in the treatment of acute-onset comitant esotropia in ch

12 progress has translated into major advances in the treatment of advanced breast cancer, with several

13 ggests that cetuximab is certainly warranted in the treatment of advanced cSCC.

14 cal activity of immune checkpoint inhibitors in the treatment of advanced melanoma.

15 ic oncolytic virus (OV) has opened a new era in the treatment of advanced melanoma; however, approxim

16 Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer

17 bination with gemcitabine has shown efficacy in the treatment of advanced PDAC and was considered to

18 The antiandrogen bicalutamide is widely used in the treatment of advanced prostate cancer (PCa) in ma

19 Conclusion Considerable shifts in the treatment of advanced-stage NSCLC occurred along

20 Catheter ablation therapy, commonly used in the treatment of AF, requires spatial information on

21 umor activity that may add therapeutic value in the treatment of aggressive breast cancers.

22 erapeutic role of anti-inflammatory cytokine in the treatment of aging-mediated insulin resistance.

23 medications that target nociceptin receptors in the treatment of alcohol use disorders.

24 Thus, CBD may have therapeutic potential in the treatment of alcoholic liver diseases associated

25 g that HA35 may be a novel therapeutic agent in the treatment of ALD.

26 , we identified an unknown mode of GC action in the treatment of allergic asthma that might help to d

27 ty of grass pollen intradermal immunotherapy in the treatment of allergic rhinitis.

28 S1 phosphorylated at Ser367 should be useful in the treatment of Alzheimer's disease.

29 tely engineered CLL-1 TDB could be effective in the treatment of AML.

30 nhibitor, as a potential co-adjuvant therapy in the treatment of AML.

31 tal stents (Fc-SEMSs) have a challenging use in the treatment of anastomosis strictures after live do

32 The use of nitroglycerin in the treatment of angina pectoris began not long after

33 assess the current landscape and challenges in the treatment of antibiotic resistance mechanisms at

34 In the treatment of anxiety disorders, attention bias mo

35 icacious as single-disorder protocols (SDPs) in the treatment of anxiety disorders.

36 As are interesting targets and/or biomarkers in the treatment of anxiety- and trauma-related disorder

37 Androgens, used in the treatment of aplastic anemia, have been reported

38 Despite advances in the treatment of asthma, optimization of symptom cont

39 it to be used as a novel therapeutic target in the treatment of asthma.

40 resulted in a 17% and 16% absolute increase in the treatment of asymptomatic and rectal STIs, respec

41 Study of the Use of Oral Posaconazole [POS] in the Treatment of Asymptomatic Chronic Chagas Disease

42 n March 2017, dupilumab was approved for use in the treatment of atopic dermatitis (eczema).

43 Antibody therapy constitutes a major advance in the treatment of B-cell precursor acute lymphoblastic

44 l finding that glucocorticoids are effective in the treatment of B-lymphoid but not myeloid malignanc

45 his concept could be particularly beneficial in the treatment of bacterial infections, by reducing th

46 ar rationale for the use of HSP90 inhibitors in the treatment of BL.

47 e medications, such as bisphosphonates, used in the treatment of bone malignancy or osteoporosis.

48 in selected tests, indicating its potential in the treatment of both cognitive and noncognitive (beh

49 rmone that is a potential therapeutic target in the treatment of both obesity and diabetes.

50 pothesize that trastuzumab most likely fails in the treatment of brain metastases of breast cancer be

51 nale for potential therapeutic interventions in the treatment of breast cancer metastasis.

52 The use of neoadjuvant systemic therapy in the treatment of breast cancer patients is increasing

53 lpha-selective therapeutics may be effective in the treatment of breast cancer patients with PIK3R1 l

54 ng chemotherapy drugs that are commonly used in the treatment of breast cancer.

55 ycycline and dapsone as valuable medications in the treatment of bullous pemphigoid.

56 ng disease-associated antigens are key tools in the treatment of cancer and autoimmunity.

57 elopment of drugs that target these networks in the treatment of cancer and other diseases.

58 Type I IFN has a long history in the treatment of cancer, but its multifaceted activit

59 ted antineoplastic agents show great promise in the treatment of cancer, having the ability to impart

60 e above challenges can lead to new paradigms in the treatment of cancer.

61 medications with demonstrated effectiveness in the treatment of cannabis withdrawal, the ability to

62 GK1 inhibitors warrant further investigation in the treatment of cardiac arrhythmias.

63 Organic nitrates are commonly used in the treatment of cardiovascular disease, but clinical

64 r (AT1R) is notable as it has a central role in the treatment of cardiovascular disease.

65 to be a safe and feasible alternative to OLR in the treatment of CCLM in selected patients.

66 Oral bacteriotherapy thus has potential in the treatment of central nervous system-related patho

67 promotion of anti-tumor CD8 T-cell responses in the treatment of certain malignancies.

68 mple, bacterial infection is a key challenge in the treatment of chronic and deep wounds.

69 lines for the use of central neuromodulators in the treatment of chronic gastrointestinal symptoms an

70 the B-cell receptor (BCR) are now prominent in the treatment of chronic lymphocytic leukemia (CLL).

71 ions is included to assist the HIV clinician in the treatment of chronic pain in this population.It i

72 izumab is superior to placebo and etanercept in the treatment of chronic plaque psoriasis.

73 evidence for omalizumab efficacy and safety in the treatment of CIndUs.

74 is article describes the practice experience in the treatment of CM, preparation of IT AmBd, and the

75 tribute to its potential therapeutic utility in the treatment of cocaine abuse.

76 imple approach to improve cisplatin efficacy in the treatment of colon cancer through the creation of

77 s with improved efficacy and safety profiles in the treatment of complex metabolic disorders.

78 Challenges in the treatment of congenital adrenal hyperplasia inclu

79 bility of using laparoscopic TPIAT (L-TPIAT) in the treatment of CP.

80 represents an important therapeutic advance in the treatment of CRPC.

81 ives and discuss their therapeutic potential in the treatment of CVD.

82 ulsants, lithium, and other medications used in the treatment of depression.

83 ulmonary fibrosis, a number may hold promise in the treatment of diabetic nephropathy, which could ev

84 Improvement in the treatment of diabetic retinopathy requires a bett

85 ocedural, and therapeutic billing codes used in the treatment of diabetic retinopathy.

86 In the treatment of disease, drugs that induce ROS are a

87 and address the potential for new therapies in the treatment of diseases and pathologies associated

88 cting these variants has clinical importance in the treatment of diseases.

89 Kv3.2 channels may therefore have potential in the treatment of disorders in which these systems hav

90 novel dynamin ligands, which could be useful in the treatment of dynamin-related disorders.

91 dations for pitavastatin as a preferred drug in the treatment of dyslipidaemia in people with HIV.

92 Cladribine has moderate clinical efficacy in the treatment of ECD and can be considered a treatmen

93 y of cladribine (2-chloro-2'-deoxyadenosine) in the treatment of ECD.

94 s blood eosinophil counts and may have value in the treatment of eosinophilic granulomatosis with pol

95 se of minimally invasive surgical techniques in the treatment of esophageal cancer.

96 highlight the need for predictive biomarkers in the treatment of esophageal cancer.

97 identify potential targets for intervention in the treatment of fear of pain and dental fear.

98 high specificity and efficacy, but their use in the treatment of fibrosis causes a high burden for pa

99 and ADAM10 as potential therapeutic targets in the treatment of fibrotic diseases.

100 Their place in the treatment of first relapse is discussed here.

101 non-union and could enable a paradigm shift in the treatment of fractures at high risk of failing to

102 nmet clinical need for cell-specific therapy in the treatment of FSGS and other proteinuric kidney di

103 pies, may offer novel therapeutic strategies in the treatment of gastrointestinal diseases associated

104 Although advances have been made in the treatment of GBM, encouraging outcomes typically

105 le modification might have a positive effect in the treatment of GERD in an urban population of Iran.

106 tive tissue graft (CTG) associated with LLLT in the treatment of gingival recession (GR) defects.

107 be considered a potential therapeutic agent in the treatment of gingivitis.

108 urally complex labdane-type diterpenoid used in the treatment of glaucoma and heart failure based on

109 s and calcineurin inhibitors are ineffective in the treatment of GVHD after LT.

110 thereby limiting the use of betaAR agonists in the treatment of heart failure.

111 ver, DTCs also have recognized medicinal use in the treatment of heavy metal poisonings as well as ha

112 B cell receptor (BCR) signaling and are used in the treatment of hematologic malignancies, block BCR-

113 results suggest the potential use of ADHLSCs in the treatment of hemophilia A.

114 l intervention, represents an important goal in the treatment of hemophilia.

115 emonstrate that DCA can be successfully used in the treatment of hemorrhagic shock in the absence of

116 safety of irreversible electroporation (IRE) in the treatment of hepatic tumors not suitable for ther

117 ity of HDV RNA is a valid surrogate endpoint in the treatment of hepatitis delta.

118 tiveness of ablative chemoembolization (ACE) in the treatment of hepatocellular carcinoma (HCC) and c

119 low-cost and low-risk alternative or adjunct in the treatment of HHD.

120 tency that may be needed if it is to be used in the treatment of HIV-1 infection.

121 enic driver alleles with clinical importance in the treatment of human cancer.

122 e checkpoint inhibitors and other strategies in the treatment of human cancer.

123 of collectrin may have therapeutic benefits in the treatment of hypertension and salt sensitivity.

124 inophil or fungal chitin-targeted inhibition in the treatment of IA.

125 CAMs have the potential to aid in the treatment of IBD, but further research is needed

126 tive effect of PRGF when used along with GTR in the treatment of IBDs in patients with CP in terms of

127 The goal in the treatment of IF is to wean children off PN throug

128 evaluated the effects of RT dose escalation in the treatment of IHCC.

129 d/or calpain activities may prove beneficial in the treatment of impaired wound healing in diabetes.

130 of phototherapy that is commonly implemented in the treatment of infants with exaggerated physiologic

131 tain outcomes between parents and caregivers in the treatment of infants with T18 and T13.

132 munomodulatory interventions play a key role in the treatment of infections and cancer as well as all

133 ne 1-phosphate (S1P) receptor (S1PR) agonism in the treatment of infectious diseases.

134 ining stability of microbial communities and in the treatment of infectious diseases.

135 ide a rationale for therapeutic use of IL-37 in the treatment of inflammation-mediated fatigue.

136 ors of TRPV1 channels are potentially useful in the treatment of inflammatory and neuropathic pain.

137 flammasome activation may offer a new option in the treatment of inflammatory bowel disease.

138 functional foods that can act as an adjuvant in the treatment of inflammatory conditions.

139 ic potential of targeting metabolic pathways in the treatment of inflammatory disease.

140 fective than administering oseltamivir alone in the treatment of influenza.

141 ed tissue regeneration (GTR) versus GTR only in the treatment of intrabony defects (IBDs) in patients

142 to conventional OFD may be potentially used in the treatment of intrabony defects.

143 chemotherapeutic drugs are often ineffective in the treatment of invasive brain tumors due to poor th

144 ential role for HIF1A or ADORA2B antagonists in the treatment of IPF.

145 We tested the efficacy of adalimumab in the treatment of JIA-associated uveitis.

146 ctor alpha monoclonal antibody, is effective in the treatment of juvenile idiopathic arthritis (JIA).

147 mpared with conventional management with PKP in the treatment of keratoconus.

148 Despite clinical advances in the treatment of KIT/PDGFRA-mutant GIST, similar prog

149 on the use of larynx-preservation strategies in the treatment of laryngeal cancer.

150 DMDD as a safe and effective antitumor agent in the treatment of late-stage breast cancer.

151 vances have been reported in the last decade in the treatment of late-stage cancer with targeted and

152 importance of time of day as a consideration in the treatment of liver metabolic disorders.

153 resents one of the most promising strategies in the treatment of lung cancer.

154 cells and lead to enhanced clinical outcomes in the treatment of lung disease with cell-based therapi

155 adjunctive lanicemine (NMDA channel blocker) in the treatment of major depressive disorder (MDD) over

156 invigorate enthusiasm for radioimmunotherapy in the treatment of malignancies, particularly lymphomas

157 K signaling pathway have shown great promise in the treatment of malignant melanoma in the last few y

158 glycerophosphoinositol can also be exploited in the treatment of manifestations of severe inflammatio

159 chemical constituents from the plant for use in the treatment of many central nervous system disorder

160 eutical protein that is clinically effective in the treatment of many human neuronal and non-neuronal

161 kpoint blockade with MDSC-targeted therapies in the treatment of mCRPC.

162 ns for the choice of chemotherapeutic agents in the treatment of Mdm2-overexpressing tumors.

163 s and provide a rationale for targeting ICMT in the treatment of metastatic cancer.

164 last 30 years, there have been many advances in the treatment of metastatic renal cell carcinoma of t

165 ests that the importance of mTORC2 inhibitor in the treatment of MFN2 downregulated cancer patients.

166 ence-based practice parameters for rituximab in the treatment of MG.

167 ernal limiting membrane peel was ineffective in the treatment of microcystoid macular changes.

168 r pregabalin as a possible effective therapy in the treatment of migraine.

169 in the long term when associated with a CTG in the treatment of Miller Class I and II GRs.

170 ion with inhibition of PD-1/PD-L1 signaling, in the treatment of MM and other B cell malignancies.

171 ts biosynthetic enzymes as potential targets in the treatment of MM.

172 an adjunct to scaling and root planing (SRP) in the treatment of moderate and severe chronic periodon

173 rnal-beam radiotherapy plays a critical role in the treatment of most pediatric solid tumors.

174 HB might represent a novel and safe strategy in the treatment of multiple bilobar CRLM.

175 HB might represent a novel and safe strategy in the treatment of multiple bilobar CRLM.

176 bitors of the proteasome have been validated in the treatment of multiple myeloma, with several FDA-a

177 hich to explore the role of IRAK4 inhibition in the treatment of mutant MYD88(L265P) diffuse large B-

178 apy, and the potential role of immunotherapy in the treatment of NETs.

179 cuss clinical developments and controversies in the treatment of neuroendocrine tumours (NETs) that a

180 of FASN, suggesting new targeted strategies in the treatment of NF2-deficient tumors.

181 reatment may be a useful adjunctive modality in the treatment of non-healing radiation wounds.

182 ed cancer therapy and marks a drastic change in the treatment of non-small cell lung cancer (NSCLC).

183 rotein (ABCG2), thereby limiting its utility in the treatment of non-small cell lung cancer metastase

184 the aorta (REBOA) is an innovative procedure in the treatment of noncompressible truncal hemorrhage.

185 dime-avibactam was non-inferior to meropenem in the treatment of nosocomial pneumonia.

186 compared to third-generation cephalosporins in the treatment of nosocomial SBP.

187 and serve as a potential therapeutic target in the treatment of OA.

188 tabolism, which has significant implications in the treatment of obesity and its associated diseases,

189 nant GDF15 protein could potentially be used in the treatment of obesity and type 2 diabetes.

190 otonin reuptake inhibitors or as monotherapy in the treatment of OCD, although their efficacy has not

191 llent biocompatibility and potential for use in the treatment of ocular diseases.

192 s and summarizes their versatile application in the treatment of ophthalmic diseases, including age-r

193 ethadone, suggesting that CDDCs have no role in the treatment of opioid-use disorders.

194 ethadone, suggesting that CDDCs have no role in the treatment of opioid-use disorders.

195 e regimens with and without systemic therapy in the treatment of OPSCC are outlined for a variety of

196 ary surgery of OPSCC, induction chemotherapy in the treatment of OPSCC, and the appropriate dose, fra

197 systemic therapy to definitive radiotherapy in the treatment of OPSCC, postoperative radiotherapy wi

198 primary cilium may have therapeutic benefits in the treatment of osteoarthritis.

199 rapeutic approach may therefore have utility in the treatment of osteonecrosis, especially in aged pa

200 preparations have a number of important uses in the treatment of other diseases in humans as well, so

201 , may be usefully combined with pitavastatin in the treatment of ovarian cancer.

202 be used as an alternative to oral sildenafil in the treatment of PAH.

203 in distal axons may provide a useful target in the treatment of pain of peripheral origin.SIGNIFICAN

204 binoid system promote opioid-sparing effects in the treatment of pain reflects an important area of r

205 kinase inhibitors might still have potential in the treatment of pancreatic cancer but further develo

206 nventional continuous deep brain stimulation in the treatment of Parkinson's disease, and helps infor

207 (2+) balance could have a direct implication in the treatment of Parkinson's patients.

208 t BCL2 and HDAC inhibition may offer synergy in the treatment of patients with advanced CTCL.

209 leased in recent years, opening new horizons in the treatment of patients with cancer.

210 bitor of Bcl2, venetoclcax, is highly active in the treatment of patients with CLL.

211 ic laser interstitial thermal therapy (LITT) in the treatment of patients with drug-resistant mesial

212 Endobronchial coils might have a role in the treatment of patients with emphysema with severe

213 combined with periodontal mechanical therapy in the treatment of patients with generalized aggressive

214 ficacy of irreversible electroporation (IRE) in the treatment of patients with inoperable hepatocellu

215 ansplantation has become a routine procedure in the treatment of patients with kidney failure, and re

216 acebo and etanercept and were well tolerated in the treatment of patients with moderate-to-severe chr

217 ting of PAK1/2/3 and MEK1/2 may be effective in the treatment of patients with MPNSTs.

218 dy that addresses two key clinical questions in the treatment of patients with newly diagnosed primar

219 The role of radiation therapy in the treatment of patients with pancreatic ductal aden

220 Dopaminergic medications used in the treatment of patients with Parkinson's disease ar

221 ETATION: Avelumab showed antitumour activity in the treatment of patients with platinum-refractory me

222 nce as compared with planned neck dissection in the treatment of patients with squamous-cell carcinom

223 y of evidence supports the use of omalizumab in the treatment of patients with therapy-refractory CIn

224 The role of incretin-based drugs in the treatment of patients with type 2 diabetes admitt

225 veness, and feasibility of early OIT (E-OIT) in the treatment of peanut allergy.

226 Dexamethasone is a key component in the treatment of pediatric acute lymphoblastic leukem

227 te the efficacy of propranolol (3 mg/kg/day) in the treatment of periocular infantile hemangioma (IH)

228 valuate the clinical utility of these agents in the treatment of Ph-like ALL.

229 mtansine group vs eight [4%] of 184 patients in the treatment of physician's choice group), neutropen

230 emtansine group and 87 (47%) of 184 patients in the treatment of physician's choice group.

231 Some lasers may be beneficial in the treatment of PIH.

232 the clinical evidence for the use of lasers in the treatment of PIH.

233 ntation.The use of gene silencing techniques in the treatment of post-transplantation host rejection

234 apitide) compared to dexamethasone eye drops in the treatment of postoperative ocular inflammation.

235 ry is noninferior to dexamethasone eye drops in the treatment of postoperative ocular inflammation.

236 ion opioid analgesics play an important role in the treatment of postoperative pain; however, unused

237 results support the efficacy of cariprazine in the treatment of predominant negative symptoms of sch

238 copic procedures have increasingly been used in the treatment of premalignant and early oesophageal t

239 of inhibition of the PKA/PPP1R1A/PP1 pathway in the treatment of primary and metastatic ES.

240 anslation of ADORA2A as a therapeutic target in the treatment of proliferative retinopathies and othe

241 Androgen deprivation therapy in the treatment of prostate cancer may be associated wi

242 y how steroids directly affect the podocytes in the treatment of proteinuria, we created a mouse mode

243 an evidence-based approach to using ketamine in the treatment of psychiatric disorders considering th

244 ALE: Existing trials of adjunctive vitamin D in the treatment of pulmonary tuberculosis (PTB) are var

245 r findings may have significant implications in the treatment of RA patients with anti-TNF-alpha drug

246 To assess low-dose naltrexone hydrochloride in the treatment of recalcitrant HHD.

247 CTL019 cells can be effective in the treatment of relapsed or refractory diffuse large

248 be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple scleros

249 LF2 in the carotid bodies may be efficacious in the treatment of respiratory and autonomic dysfunctio

250 limumab and methotrexate combination therapy in the treatment of rheumatoid arthritis in patients wit

251 eu, alone or in combination with other AMPs, in the treatment of S. aureus intravenous catheter infec

252 raining is gaining empirical support for use in the treatment of schizophrenia (SZ).

253 inhibitors, and combination immunotherapies in the treatment of select virus-associated cancers.

254 al-life' effectiveness studies of omalizumab in the treatment of severe allergic asthma that included

255 body titres to influenza might be of benefit in the treatment of severe influenza.

256 Cryotherapy is commonly used in the treatment of skeletal muscle injuries.

257 uction of Aiolos and Ikaros may have utility in the treatment of SLE, where elevated levels of BAFF a

258 at the Bim may be a novel therapeutic target in the treatment of SLE.

259 in the pathogenesis, along with developments in the treatment of sleep apnea, have accumulated in rec

260 a resurgence of enthusiasm for immunotherapy in the treatment of solid tumours.

261 of anti-programmed death 1 (PD-1) antibodies in the treatment of solid-organ tumors, with an estimate

262 Despite recent advances in the treatment of some forms of lung fibrosis, many ga

263 Pregabalin is effective in the treatment of some types of neuropathic pain.

264 own to be superior to ATRA plus chemotherapy in the treatment of standard-risk patients with newly di

265 They are also used in the treatment of subsets of patients with heart failu

266 zymatic properties could play a crucial role in the treatment of such pathologies.

267 for larger clinical studies of fondaparinux in the treatment of suspected HIT.

268 cacy Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe Aortic Stenosis i

269 e potential therapeutic use of this antibody in the treatment of systemic amyloidosis.

270 d protein translation inhibitor combinations in the treatment of T-ALL.

271 nstrated favorable efficacy and tolerability in the treatment of tardive dyskinesia in phase 2 studie

272 ral Na(+) movement is predicted to be useful in the treatment of temperature-dependent symptoms under

273 otentiators like PF-04958242 may have a role in the treatment of the cognitive symptoms, but not the

274 receptor (BCR) pathway have been successful in the treatment of the disease, the underlying mechanis

275 is C was the key reason for the good results in the treatment of the second eye, remains elusive.

276 ermine the role mGluR5 modulation might play in the treatment of these conditions.

277 suggest an important role for acalabrutinib in the treatment of this disease population.

278 The increased use of antidopaminergics in the treatment of this disorder and new in vivo neuroi

279 gramming of PSCs may be a viable alternative in the treatment of this lethal disease.

280 ient cohort clearly confirms the value of LT in the treatment of this rare disorder and also permits

281 ry, functional neurosurgery has been applied in the treatment of tremor.

282 esistant tuberculosis threatens recent gains in the treatment of tuberculosis and human immunodeficie

283 hown some remarkable and prolonged responses in the treatment of tumors.

284 is better tolerated than intravenous boluses in the treatment of type 1 HRS.

285 LP-1) make it a potent candidate drug target in the treatment of type 2 diabetes mellitus (T2DM).

286 Despite widespread clinical use in the treatment of type 2 diabetes, the impact of sulfo

287 tion of ready-to-use therapeutic food (RUTF) in the treatment of uncomplicated SAM, in terms of clini

288 showed comparable efficacy and safety to A-L in the treatment of uncomplicatedP. falciparummalaria in

289 TACE) combined with microwave ablation (MWA) in the treatment of unresectable solitary hepatocellular

290 nt with pharmacological properties effective in the treatment of various ailments including hepatitis

291 component smoothened (Smo) has shown promise in the treatment of various cancers including pancreatic

292 cy and reducing the toxicity of therapeutics in the treatment of various disease conditions.

293 lial protection supporting its potential use in the treatment of vascular cognitive impairment.

294 iodarone (AMD) and nifekalant (NIF) are used in the treatment of ventricular fibrillation or tachycar

295 n, which, so far, have not shown any benefit in the treatment of vertebral or basilar artery stenosis

296 nt of pronucleotide (ProTide) therapies used in the treatment of viral disease and cancer.

297 notherapy is proving to be a useful strategy in the treatment of virus-associated cancers.

298 the utility of cytokine-targeting strategies in the treatment of virus-infected individuals with impa

299 d be safely considered for future evaluation in the treatment of wet AMD.

300 vitreal anti-VEGF injections are widely used in the treatment of wet-AMD and PDR.